128 related articles for article (PubMed ID: 7927134)
1. Treatment of GVHD after blood transfusion.
Sakuma H; Kikuta A; Suzuki H
Fukushima J Med Sci; 1993 Dec; 39(2):113-6. PubMed ID: 7927134
[TBL] [Abstract][Full Text] [Related]
2. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation in thalassemia major patients using "short" anti-thymocyte globulin therapy in Shiraz, Southern Iran.
Zakerinia M; Khojasteh HN; Ramzi M; Haghshenas M
Transplant Proc; 2005 Dec; 37(10):4477-81. PubMed ID: 16387149
[TBL] [Abstract][Full Text] [Related]
4. Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.
Mehta J; Powles R; Singhal S; Iveson T; Treleaven J; Catovsky D
Bone Marrow Transplant; 1996 Mar; 17(3):371-5. PubMed ID: 8704689
[TBL] [Abstract][Full Text] [Related]
5. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal.
Oliveira JS; Bahia D; Franco M; Balda C; Stella S; Kerbauy J
Bone Marrow Transplant; 1999 Jan; 23(1):99-101. PubMed ID: 10037059
[TBL] [Abstract][Full Text] [Related]
6. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
Basić-Jukić N; Labar B
Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
[TBL] [Abstract][Full Text] [Related]
7. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
8. Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation.
Karwacka E; Ołdakowska-Jedynak U; Brydak-Godowska J; Paczek L; Kecik D
Transplant Proc; 2006; 38(1):292-4. PubMed ID: 16504728
[TBL] [Abstract][Full Text] [Related]
9. Graft-versus-host disease in allogeneic bone marrow transplantation: the role of monoclonal antibodies in prevention and treatment.
Hiscott A; McLellan DS
Br J Biomed Sci; 2000; 57(2):163-9. PubMed ID: 10912294
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
Schwinghammer TL; Bloom EJ
Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases.
Tauchmanovà L; Selleri C; Rosa GD; Pagano L; Orio F; Lombardi G; Rotoli B; Colao A
Cancer; 2002 Sep; 95(5):1076-84. PubMed ID: 12209694
[TBL] [Abstract][Full Text] [Related]
12. Systematic management of graft-versus-host disease (GVHD).
Matsumoto Y; Akama Y; Tase C; Okuaki A
Fukushima J Med Sci; 1993 Dec; 39(2):117-9. PubMed ID: 7927135
[TBL] [Abstract][Full Text] [Related]
13. Anti-host cytotoxic T cells of bone marrow transplant recipients with or without graft-versus-host disease are equally sensitive to cyclosporin A.
Liem LM; van Noort JT; Goulmy E
Bone Marrow Transplant; 1996 Jul; 18(1):73-8. PubMed ID: 8831998
[TBL] [Abstract][Full Text] [Related]
14. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
[TBL] [Abstract][Full Text] [Related]
15. [Digestive manifestations of graft-versus-host disease (GVHD) in bone marrow transplantation, organ transplantation and transfusion].
Li V; Molina L; Michallet M; Hostein J
Gastroenterol Clin Biol; 1992; 16(1):29-36. PubMed ID: 1537479
[No Abstract] [Full Text] [Related]
16. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease.
Tse JC; Moore TB
Pharmacotherapy; 1998; 18(5):988-1000. PubMed ID: 9758310
[TBL] [Abstract][Full Text] [Related]
18. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
[TBL] [Abstract][Full Text] [Related]
19. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
20. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients.
Min CK; Eom KS; Lee S; Kim DW; Lee JW; Min WS; Kim CC
Bone Marrow Transplant; 2001 May; 27(9):999-1005. PubMed ID: 11436112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
